5 documents found, page 1 of 1
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA...
Lanièce Delaunay, Charlotte; Martínez-Baz, Iván; Sève, Noémie; Domegan, Lisa; Mazagatos, Clara; Buda, Silke; Meijer, Adam; Kislaya, IrinaBackground: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SAR...
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Va...
Maurel, Marine; Pozo, Francisco; Pérez‐Gimeno, Gloria; Buda, Silke; Sève, Noémie; Oroszi, Beatrix; Hooiveld, Mariette; Gómez, Verónica; Domegan, LisaBackground: Influenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Materials and methods: Primary care practitioners collected information and specimens from patients consulting with acut...
Vaccine effectiveness against influenza hospitalisation in adults during the 20...
Rose, Angela M. C.; Pozo, Francisco; Martínez‐Baz, Iván; Mazagatos, Clara; Bossuyt, Nathalie; Cauchi, John Paul; Petrović, Goranka; Loghin, Isabela I.We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (...
Effectiveness of influenza vaccine against influenza A in Europe in seasons of ...
Kissling, Esther; Pozo, Francisco; Buda, Silke; Vilcu, Ana-Maria; Rizzo, Caterina; Gherasim, Alin; Krisztina Horváth, Judit; Brytting, MiaIntroduction: Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods: We used the test-negative ...
Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-ol...
Kissling, Esther; Pozo, Francisco; Buda, Silke; Vilcu, Ana-Maria; Gherasim, Alin; Brytting, Mia; Domegan, Lisa; Gómez, Verónica; Meijer, AdamIntroduction: Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim: The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods: We measured VE ag...